VEGFA and cancer: The enrichment of biological pathways was consistent with the drug sensitivity results (Table S4 and Figure 6), showing that TAK-715 (MAPK inhibitor) and XL-184 (VEGF inhibitor) had good efficacy on cancer treatment.